Pharmacokinetics and Bioequivalence of Two Fixed-Dose Combination Tablets of Valsartan/Amlodipine (80/5 Mg) in Healthy Chinese Subjects

• Published in: Drug design, development and therapy Vol. 19; pp. 11 - 22
• Main Authors: Tian, Mengli, Huang, Jinlong, Chen, Yingrong, Jin, Qiuyue, Jiang, Hong, Shi, Cunyuan, Mei, Jue, Xu, Min, Yu, Xiang, Yang, Shuixin
• Format: Journal Article
• Language: English
• Published: New Zealand Dove 01.01.2025; Dove Medical Press
• Subjects: Administration, Oral; Adult; amlodipine; Amlodipine - administration & dosage; Amlodipine - pharmacokinetics; Amlodipine, Valsartan Drug Combination - administration & dosage; Amlodipine, Valsartan Drug Combination - pharmacokinetics; bioequivalence; Chromatography, High Pressure Liquid; Clinical Trial Report; Cross-Over Studies; East Asian People; Female; Healthy Volunteers; Humans; Male; pharmacokinetics; safety; Tablets; Tandem Mass Spectrometry; Therapeutic Equivalency; valsartan; Valsartan - administration & dosage; Valsartan - pharmacokinetics; Young Adult; pharmacokinetics; valsartan; safety; amlodipine; bioequivalence
• ISSN: 1177-8881; 1177-8881
• DOI: 10.2147/DDDT.S485851

The study aimed to investigate the pharmacokinetics and bioequivalence of coformulations of valsartan and amlodipine in healthy Chinese subjects under both fasting and fed conditions. The research was conducted under both fasting and fed studies and employed a single-center, randomized, open-label, single-dose, three-period design with partial-repeat and crossover elements. A total of 71 healthy Chinese adult participants were included under fasting (n = 36) and fed (n = 35) conditions. The subjects were orally administered valsartan/amlodipine tablets (80/5 mg) per cycle either as the test (T) or reference (R) formulation. The washout period was 14 days. Plasma concentrations of valsartan and amlodipine were determined using ultrahigh-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), and the noncompartmental analysis method was used for estimating the pharmacokinetic parameters. Under fasting conditions, the within-subject standard deviations (S ) of maximum plasma concentration (C ), area under the concentration-time curve from time 0 to the time of the last-measurable plasma concentration (AUC ), and area under the concentration-time curve from time 0 extrapolated to infinity (AUC ) for valsartan were calculated to be ≥0.294 and evaluated by the reference-scaled average bioequivalence (RSABE) method. The point estimates of the geometric mean ratios (GMRs) of C , AUC and AUC for valsartan were 1.0805, 1.0991, and 1.1015 respectively, and the critical bounds were all less than 0. The S of C , AUC , and AUC for amlodipine were all <0.294, and the 90% confidence intervals (CIs) of the GMRs fell within the bioequivalence range, as evaluated by the average bioequivalence (ABE) method. Under the fed condition, the S of C , AUC , and AUC were all <0.294 for both valsartan and amlodipine; the ABE method was therefore employed for the evaluation of bioequivalence, and the 90% CIs of the GMRs fell within the bioequivalence range. All the observed adverse events were mild and transient. The two formulations of valsartan/amlodipine (80/5 mg) tablets were bioequivalent and safe.